Clinical trials: HIV Antibodies
HIV Infection of the Uterine Vaginal Tissues
First Event of Infection by HIV-1 of Uterine Vaginal Tissue
This non-interventional study aims to characterize the cells infected with HIV over time in different types of vagino-uterine tissue.
- Trial name
- NCT02481622
- Where
- France
- Volunteers
- 600 people
- Sponsor
- University Hospital, Strasbourg, France
HIV -1 Infection
HIV-1 Virologic Suppression With TMB-365 and TMB-380 Antibodies Study
TMB-365 is a monoclonal antibody that binds to the CD4 receptor. TMB-380, aka VRC07-523LS is a monoclonal antibody that binds to HIV. Both interfere with HIV entry.
- Trial name
- VISTA (NCT07215468)
- Testing
- TMB-365, TMB-380, Baseline ART
- Where
- 10 sites in United States
- Volunteers
- 88 people
- Sponsor
- TaiMed Biologics Inc.
HIV-1 Infected Adults With Controlled Viremia
Safety and Tolerability of AAV8 Delivery of a Broadly Neutralizing Antibody in Adults Living With HIV: a Phase 1, Dose-escalation Trial
Background: The Human Immunodeficiency Virus (HIV) attacks the immune system. Scientists have created a gene that could be transferred to the cells of people with HIV.
- Trial name
- VRC 603 (NCT03374202)
- Testing
- VRC-HIVAAV070-00-GT (AAV8-VRC07)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Prevention
Evaluating the Safety and Immunogenicity of Polyvalent DNA and Recombinant gp120 Protein HIV Vaccine (PDPHV) in Healthy, HIV-uninfected Adults
The purpose of the study is to evaluate the safety, tolerability, and immunogenicity of polyvalent env (A,B,C,A/E)/gag (C) DNA prime and gp120 (A,B,C,A/E) protein HIV-1 vaccines boost (PDPHV) with either Alhydrogel or GLA-SE in…
- Trial name
- NCT07675629
- Testing
- PDPHV Plasmid DNA Vaccines (env (A, B, C, A/E)/gag (C)), PDPHV Recombinant Protein Vaccines (gp120 (A, B, C, A/E)), Alhydrogel adjuvant
- Where
- 2 sites in United States, South Africa
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Worcester HIV Vaccine
HIV-1 Infection, Neutralizing Antibody
VRC 601: A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC HIVMAB060-00-AB (VRC01), With Broad HIV-1 Neutralizing Activity, Administered Intravenously or Subcutaneously to HIV-Infected...
This is the first clinical trial of the VRC-HIVMAB060-00-AB (VRC01) monoclonal antibody. VRC01 is a broadly neutralizing antibody directed against HIV.
- Conditions
- HIV-1 Infection, Neutralizing Antibody, Monoclonal Antibody, Viral Load
- Trial name
- NCT01950325
- Testing
- VRC-HIVMAB060-00-AB
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hiv, HIV/AIDS
N-803 Combined With the Broadly Neutralizing Antibodies Plus or Minus haNK Cells for HIV
To assess the safety of combination immune therapy in HIV-infected participants whose HIV is controlled with ART, by determining the incidence and severity of adverse events.
- Conditions
- Hiv, HIV/AIDS, HIV Infections, AIDS
- Trial name
- NCT04144335
- Testing
- N-803 and bNAbs, haNK™ Cells
- Where
- 3 sites in United States
- Sponsor
- University of Minnesota
HIV Antibody Testing
Use of OraQuick for Screening HIV in Children Less Than Eighteen Months Old
Blood is the most commonly used specimen to test for HIV. In the past 20 years, use of saliva as an alternative specimen for HIV testing has been explored.
- Trial name
- NCT00378118
- Testing
- Abbott-rapid HIV antibody test, OraQuick Rapid HIV-1/2 Antibody test
- Where
- Zambia
- Volunteers
- 1,000 people
- Sponsor
- Thrasher Research Fund
HIV Infections
Safety and Effectiveness of Anti-HIV Vaccines in HIV-Negative Adults
The purpose of this study is to find out whether three different anti-HIV vaccines are safe and whether they help prevent HIV infection. These vaccines are called vCP205, vCP1433, and vCP1452.
- Trial name
- NCT00000904
- Testing
- ALVAC(2)120(B,MN)GNP (vCP1452), gp160 MN/LAI-2, ALVAC(1)120(B,MN)GNP (vCP1433)
- Where
- 6 sites in United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Liver Fibrosis, Hepatitis C
Study of Simtuzumab in HIV and/or Hepatitis C- Infected Adults With Liver Fibrosis
The primary objective of this study is to assess the safety and tolerability of simtuzumab (formerly GS-6624) in HIV and/or hepatitis C virus (HCV)-infected adults with evidence of liver fibrosis.
- Conditions
- Liver Fibrosis, Hepatitis C, HIV, HIV/HCV Co-infection
- Trial name
- NCT01707472
- Testing
- Simtuzumab
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Gilead Sciences
HIV
PRO 140 for Human Immunodeficiency Virus
PRO 140 2102 is a multicenter, randomized, double-blind, placebo-controlled, clinical trial of observed systemic, long-acting, anti-HIV treatment with a monoclonal CCR5 antibody (PRO 140) as an adjunct to a new, optimized, oral…
- Trial name
- NCT02438345
- Testing
- PRO 140
- Where
- United States
- Sponsor
- Drexel University
Lymphoma
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Previously Untreated HIV-Associated Non-Hodgkin's Lymphoma
Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without monoclonal antibody therapy in treating patients who have previously untreated HIV-associated non-Hodgkin's lymphoma.
- Trial name
- NCT00003595
- Testing
- filgrastim, rituximab, CHOP regimen
- Where
- 13 sites in United States
- Volunteers
- 120 people
- Sponsor
- National Cancer Institute (NCI)
HIV Infections
Immune Response to Toll-Like Receptor 9-Agonist Adjuvanted Pneumococcal Vaccination in HIV Infected Adults
The purpose of this study is to determine whether TLR-9 adjuvanted pneumococcal is more immunogenic than pneumococcal vaccination alone in HIV-infected adults.
- Trial name
- ITAP (NCT00562939)
- Testing
- Pneumococcal vaccines + CPG 7909, Pneumococcal vaccines
- Where
- Denmark
- Volunteers
- 97 people
- Sponsor
- University of Aarhus
Kaposi's Sarcoma, HIV Infections
Bevacizumab to Treat Kaposi's Sarcoma in HIV-Positive and HIV-Negative Patients
This study will examine the safety and effectiveness of the experimental drug bevacizumab for treating both non-acquired immune deficiency syndrome (AIDS) and AIDS-associated Kaposi's sarcoma (KS).
- Conditions
- Kaposi's Sarcoma, HIV Infections, HIV Seronegativity
- Trial name
- NCT00055237
- Testing
- Bevacizumab
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
HIV
Combination Therapy With VRC01 and 10-1074 in HIV-Infected Individuals Undergoing Sequential Treatment Interruptions
Background: A daily drug combination can keep human immunodeficiency virus (HIV) levels low for a long time. But if this combination antiretroviral therapy (ART) stops, HIV levels go back up.
- Trial name
- NCT03831945
- Testing
- VRC-HIVMAB060-00-AB (VRC01), 10-1074
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Covid19, SARS-CoV Infection
A Registry Study of COVID-19 Serologic and Virologic Testing to Accelerate Recovery and Transition
The co-primary objectives of this study are to: 1. Determine and compare the COVID-19 antibody positivity rate in health care workers and patients without a known COVID-19 infection 2.
- Trial name
- START (NCT04573634)
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Jill M Kolesar
HIV Infections
A Phase 1, Randomized, Blinded, Dose-escalation Study of rAAV1-PG9DP Recombinant AAV Vector Coding for PG9 Antibody in Healthy Male Adults.
The purpose of this study is to evaluate the safety, tolerability and immunogenicity of rAAV1-PG9DP when administered intramuscularly at different dose levels in healthy male adults.
- Trial name
- NCT01937455
- Testing
- rAAV1-PG9DP
- Where
- 2 sites in United Kingdom
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- International AIDS Vaccine Initiative
HIV/AIDS
A Phase 1/2a Study of PGT121, VRC07-523LS and PGDM1400 Monoclonal Antibodies in HIV-uninfected and HIV-infected Adults
This is a Phase 1/2a open label study to evaluate the safety, tolerability, pharmacokinetics and anti-viral activity of PGT121, VRC07-523LS and PGDM1400 for HIV prevention and therapy.
- Trial name
- NCT03721510
- Testing
- PGT121 + VRC07-523LS, PGT121 + VRC07-523LS + PGDM1400
- Where
- 3 sites in United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- International AIDS Vaccine Initiative
HIV Infections, HIV Seronegativity
Studies of HIV-1 Infection in Newly Infected Individuals in Southern Africa
The main goal of this study is to find out how the immune system responds to a specific type of HIV infection, known as C HIV-1, in order to develop a vaccine against this type of infection.
- Trial name
- NCT00006298
- Where
- United States
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Household Contacts
A Study to Evaluate AAV9 Neutralizing Antibody Seroconversion in Household Contacts.
This study will include male and female participants who live or work in the same household as a patient in one of the fordadistrogene movaparvovec interventional studies.
- Trial name
- NCT04543357
- Testing
- Blood Draw
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Pfizer
HIV Infections
Effectiveness of Adding Remune to Your Current Anti-HIV Drug Combination
The purpose of this study is to see if giving a vaccine (Remune) is effective in HIV-positive patients who are also taking anti-HIV therapy.
- Trial name
- NCT00006153
- Testing
- HIV-1 Immunogen
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)